TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05395910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
Study: NCT05784480

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Checklist for evaluation of reversible causes
Description: Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
Study: NCT05344313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus Advance
Description: as in the arm description of the intervention
Study: NCT04605887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angiotensin 1-7
Description: Ang 1-7 subcutaneously 500 mcg/kg /day
Study: NCT05348213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus R-ICE
Description: Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus R-ICE
Description: Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide plus R-ICE
Description: Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus R-ICE
Description: Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus R-ICE
Description: Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study: NCT04605887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin 1-7
Description: Ang 1-7 subcutaneously 500 mcg/kg /day
Study: NCT04950725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength RMT
Description: 2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength RMT and nasal breathing
Description: 2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance RMT
Description: 15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance RMT and nasal breathing
Description: 15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose RMT
Description: 10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
Study: NCT06023277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ConvitVax
Description: ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
Study: NCT05727254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Agility training
Description: Multi-component (strength, balance, cognition) exercise training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise recommendations
Description: Participants are being given the standard recommendations how much exercise and what type older adults should do.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise recommendations
Description: Participants are being given the standard recommendations how much exercise and what type older adults should do.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise diary
Description: Participants are instructed to write down their physical activity and exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise diary
Description: Participants are instructed to write down their physical activity and exercises.
Study: NCT06101433

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavone
Description: the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
Study: NCT06243419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vein viewer
Description: The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: The child watched the application by wearing virtual glasses during the PIC insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vein viewer and virtual reality
Description: The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion
Study: NCT05566314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amunizer
Description: 12 oz. herbal, probiotic and antioxidant herbal beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 oz. flavored beverage
Study: NCT06655623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schema therapy
Description: Schema therapy is a form of psychotherapy invented to address more complex clinical cases. It consists of elements from Cognitive Behavioral Therapy as well as psychodynamic, emotion-focused and gestalt therapies, with a distinct focus on experiential interventions. A therapy manual was developed for use in this study.
Study: NCT06655818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab Mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study: NCT06654154

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: variation of serum level vitamine B12
Description: There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture
Study: NCT05263479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089 (Phase Ia：Dose escalation )
Description: Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT06589076

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and Radiographic assessment + Questionnaires
Description: * Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and Radiographic assessment + Questionnaires
Description: * Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression.
Study: NCT06590766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
Study: NCT05263479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089 (Phase Ib: Dose expansion)
Description: IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT06590766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupressure/relaxation with acupuncture
Description: The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
Study: NCT06599853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fever Education
Description: Another aspect of this research that is different from other studies is that a retention test will be applied to the participants after the pre-test and post-test, and the long-term effect of the training given will be examined. In this direction, it is aimed to reduce the inappropriate use of emergency services, the use of unnecessary tests and the increasing health system costs. It is aimed to prevent crowding in the emergency department by reducing the inappropriate use of emergency services.
Study: NCT06591221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chuna Maintenance Therapy
Description: it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chuna Maintenance Therapy
Description: it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner.
Study: NCT06595394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in the experimental group will receive treatment for 8 weeks, 3 sessions per week. Each treatment session will be planned to last 60 minutes. People in the experimental group will receive a combined exercise training consisting of aerobic exercise, balance exercise and strengthening exercises for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home program
Description: The control group will be followed with a home program for 8 weeks. Patients will be asked to apply the home program, which includes traditional physiotherapy practices, 3 days a week and this will be followed by physiotherapists.
Study: NCT06592378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Addinex
Description: Medication dispensing system to control and monitor opioid use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Addinex
Description: Medication dispensing system to control and monitor opioid use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pill Bottle
Description: Access and use of opioids in a standard pill bottle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pill Bottle
Description: Access and use of opioids in a standard pill bottle.
Study: NCT06590259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-mode tumor treatment system
Description: All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. Complete ablation of intrahepatic lesions is achieved to realize an intrahepatic no-evidence-of-disease (NED) state. For lesions that could not be ablated in a single session, two treatments are performed to achieve NED within the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
Description: Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
Study: NCT06313307

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: topical H2R antagonist
Description: Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied topically twice per day in the morning and the evening for 16 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium 1927-nm Fractional Laser
Description: 1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium 1927-nm Fractional Laser
Description: 1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
Study: NCT04979312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabClasp
Description: Subjects will complete up to 10 measurements per day with potentially more before and during their OGTT using the LabClasp
Study: NCT06655259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURP
Description: Participants will undergo Transurethral Resection of the Prostate (TURP), a surgical procedure performed to relieve symptoms of urinary obstruction caused by the prostate tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
Study: NCT06655571

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided caudal Block
Description: caudal block using Ultrasound

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventionel
Description: Caudal Block based on anatomical landmarks
Study: NCT06595862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EA-Avatar
Description: The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement.
Study: NCT05633602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT04938024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is a commercially available over-the-counter food supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is a commercially available over-the-counter food supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C is a commercially available over-the-counter food supplement.
Study: NCT05617352

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions

Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions
Study: NCT04844801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk control strategy
Description: * Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance \>30 mL/min)~* Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rate control strategy:
Description: * Risk-control as described above~* Low dose amiodarone:~  * Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~ * Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control strategy:
Description: * Risk control as described above~* High dose amiodarone:~  * Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~ * Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~* NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses \> 0.3 µg/kg/min;~* NOSVA persists more than 6 hrs after initial amiodarone bolus.
Study: NCT05925556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal Coping Intervention
Description: The components of the intervention were described in the experimental arm.
Study: NCT05830409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensorial Stimulation
Description: Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
Study: NCT06080893

Intervention type: DRUG
Intervention: Ferric carboxymaltose
Description: FCM can be administered in a short IV infusion of 15-20 minutes, allowing doses of 2 g in a single session, and furthermore, FCM is excellently tolerated and safe for patients.~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level
Study: NCT05735795

Intervention type: OTHER
Group type: OTHER
Intervention: Carbon Black Tattoo
Description: SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
Study: NCT06078839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate
Description: Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose
Description: Add 50ml of 5% glucose into a 50ml syringe
Study: NCT06178406

Intervention type: BEHAVIORAL
Intervention: dysmenorrhea
Description: Dysmenorrhea, defined as painful menstrual cramps of uterine origin, is the most common gynecological condition among women of reproductive age.